FibroBiologics Competitors
| FBLG Stock | 0.34 0.01 3.03% |
FibroBiologics Common vs Hoth Therapeutics Correlation
Very weak diversification
The correlation between FibroBiologics Common Stock and HOTH is 0.49 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding FibroBiologics Common Stock and HOTH in the same portfolio, assuming nothing else is changed.
Moving against FibroBiologics Stock
| 0.57 | MOLN | Molecular Partners | PairCorr |
| 0.51 | ARWR | Arrowhead Pharmaceuticals | PairCorr |
| 0.31 | CRDF | Cardiff Oncology Buyout Trend | PairCorr |
FibroBiologics Common Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between FibroBiologics Common and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of FibroBiologics and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of FibroBiologics Common does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between FibroBiologics Stock performing well and FibroBiologics Common Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze FibroBiologics Common's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DARE | 3.04 | (0.12) | 0.00 | (0.08) | 0.00 | 6.55 | 26.52 | |||
| ATHA | 4.22 | 1.03 | 0.26 | 0.88 | 3.40 | 7.83 | 70.38 | |||
| ADTX | 11.10 | (3.76) | 0.00 | (3.75) | 0.00 | 22.54 | 63.67 | |||
| AIMD | 4.08 | (0.57) | 0.00 | (0.26) | 0.00 | 11.43 | 28.00 | |||
| CTXR | 4.59 | (1.16) | 0.00 | (0.56) | 0.00 | 10.59 | 38.23 | |||
| MBRX | 4.68 | (1.39) | 0.00 | (1.48) | 0.00 | 9.37 | 41.63 | |||
| LPTX | 14.85 | 6.79 | 0.64 | (1.21) | 6.90 | 25.00 | 65.13 | |||
| APLM | 6.78 | 0.11 | 0.00 | (0.05) | 9.27 | 17.08 | 44.38 | |||
| ICU | 4.80 | (1.22) | 0.00 | (0.61) | 0.00 | 9.58 | 34.66 | |||
| HOTH | 2.54 | (0.60) | 0.00 | (0.44) | 0.00 | 4.81 | 14.85 |
Cross Equities Net Income Analysis
Compare FibroBiologics Common and related stocks such as Dare Bioscience, Athira Pharma, and Aditxt Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DARE | (19.6 M) | (19.6 M) | (22.1 M) | (17.1 M) | (23.3 M) | (39.6 M) | (39.3 M) | (11.5 M) | (16.7 M) | (14.3 M) | (27.4 M) | (38.7 M) | 406.8 M | (30.2 M) | (4.1 M) | (4.7 M) | (4.4 M) |
| ADTX | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (32.4 M) | (34.4 M) | (31 M) | (32.6 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| CTXR | (26.3 K) | (22 K) | (31.4 K) | (1.3 M) | (2.9 M) | (8.3 M) | (10.4 M) | (12.5 M) | (15.6 M) | (17.5 M) | (23.1 M) | (33.6 M) | (32.5 M) | (39.1 M) | (37.4 M) | (33.7 M) | (32 M) |
| MBRX | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (3.9 M) | (9.8 M) | (11.9 M) | (13.2 M) | (17.4 M) | (15.9 M) | (29 M) | (29.8 M) | (21.8 M) | (19.6 M) | (20.6 M) |
| APLM | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (74.8 M) | (94.8 M) | (240.8 M) | (172.6 M) | (53.9 M) | (48.5 M) | (50.9 M) |
| ICU | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (23 M) | (26.2 M) | (24.8 M) | (22.3 M) | (23.5 M) |
| HOTH | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2.5 M) | (7.7 M) | (7.2 M) | (14.3 M) | (11.4 M) | (7.8 M) | (8.2 M) | (7.4 M) | (7.7 M) |
FibroBiologics Common and related stocks such as Dare Bioscience, Athira Pharma, and Aditxt Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in FibroBiologics Common financial statement analysis. It represents the amount of money remaining after all of FibroBiologics Common Stock operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.FibroBiologics Common Competitive Analysis
The better you understand FibroBiologics Common competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, FibroBiologics Common's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across FibroBiologics Common's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
FibroBiologics Common Competition Performance Charts
Five steps to successful analysis of FibroBiologics Common Competition
FibroBiologics Common's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by FibroBiologics Common in relation to its competition. FibroBiologics Common's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of FibroBiologics Common in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact FibroBiologics Common's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to FibroBiologics Common, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your FibroBiologics Common position
In addition to having FibroBiologics Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Technology Thematic Idea Now
Technology
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
| View All Next | Launch |
Check out FibroBiologics Common Correlation with its peers. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Can Biotechnology industry sustain growth momentum? Does FibroBiologics have expansion opportunities? Factors like these will boost the valuation of FibroBiologics Common. Market participants price FibroBiologics higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating FibroBiologics Common demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, FibroBiologics Common's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.